Investment In Montrose Facility And Expansion Of Stela And Pola Expected To Strengthen Future Market Position

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

18 Feb 25

Updated

01 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-14.0%

-1.0%

-14.0%

-1.0%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

AU$1.326.9% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates8

Shared on 01 May 25

Fair value Increased 0.78%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

Fair value Decreased 0.77%

AnalystConsensusTarget has increased revenue growth from 4.0% to 5.1%.

AnalystConsensusTarget Fair Value

AU$1.3

26.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.00%

Medical Equipment revenue growth rate

7.91%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.63%

Calculation

AU$16.72m

Earnings '28

11.40x

PE Ratio '28

AU$190.55m

Market Cap '28

AU$190.55m

Market Cap '28

118.87m

No. shares '28

AU$1.60

Share Price '28

AU$1.60 Share Price '28

Discounted to 2025 @ 7.50% p.a.

AU$1.29

Fair Value '25